ROS proto-oncogene 1 (ROS1) rearrangements are reported in about 1–2% of non-
squamous non-small-cell lung cancer (NSCLC). After efficacy of crizotinib was …

ROS1 rearrangement characterizes a small subset (1%–2%) of non-small cell lung cancer
and is associated with slight/never smoking patients and adenocarcinoma histology …

Background ROS proto-oncogene 1 (ROS1) rearrangements are a known molecular target
in non–small-cell lung cancer (NSCLC). Our goal was to determine whether ROS1 …

ROS1 rearrangements are identified in 1–2% of lung adenocarcinoma cases, and reflex
testing is guideline-recommended. We developed a decision model for population-based …

Introduction Crizotinib provided meaningful clinical benefit in the initial analysis of a phase 2
study in East Asian patients with advanced ROS1-positive NSCLC (NCT01945021) …

This review article highlights some important points in the evolving area of predictive
biomarkers determination in non-small-cell lung cancer toward standardization of testing …

The ROS1 kinase is an oncogenic driver in non-small-cell lung cancer (NSCLC). Fusion
events involving the ROS1 gene are found in 1%–2% of NSCLC patients and lead to …

Abstract Background ROS1 rearrangements (ROS1+) define a distinct molecular subset of
lung adenocarcinomas. ROS1+ tumors are known to occur more in never-smokers, but the …

(1) Background: The C-ros oncogene 1 (ROS1) gene translocation is an important
biomarker for selecting patients for crizotinib-targeted therapy. The aim of this study was to …

Targeted therapies are playing an increasing role in oncology. Among them, particular
attention is nowadays reserved to histology-agnostic treatments. Rare molecular alterations …